Th-1, Th-2, Th-9, Th-17, Th-22 type cytokine concentrations of critical COVID-19 patients after treatment with Remdesivir.
COVID-19
Critical COVID-19 patients
Cytokines storm
Inflammatory cytokines
Remdesivir treatment
SARS-CoV-2
Th1-type cytokines
Th17-type cytokines
Th2-type cytokines
Journal
Immunobiology
ISSN: 1878-3279
Titre abrégé: Immunobiology
Pays: Netherlands
ID NLM: 8002742
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
23
11
2022
revised:
22
02
2023
accepted:
20
03
2023
medline:
14
6
2023
pubmed:
15
4
2023
entrez:
14
4
2023
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread around the world causing a pandemic known as coronavirus disease 2019 (COVID-19). Cytokine storm was directly correlated with severity of COVID-19 syndromes. We evaluated the levels of 13 cytokines in ICU hospitalized COVID-19 patients (n = 29) before, and after treatment with Remdesivir as well as in healthy controls (n = 29). Blood samples were obtained from ICU patients during ICU admission (before treatment) and 5 days after treatment with Remdesivir. A group of 29 age- and gender-matched healthy controls was also studied. Cytokine levels were evaluated by multiplex immunoassay method using a fluorescence labeled cytokine panel. In comparison to cytokine levels measured at ICU admission, serum levels were reduced of IL-6 (134.75 pg/mL vs. 20.73 pg/mL, P < 0.0001), TNF-α (121.67 pg/mL vs. 10.15 pg/mL, P < 0.0001) and IFN-γ (29.69 pg/mL vs. 22.27 pg/mL, P = 0.005), whereas serum level was increased of IL-4 (8.47 pg/mL vs. 12.44 pg/mL, P = 0.002) within 5 days after Remdesivir treatment. Comparing with before treatment, Remdesivir significantly reduced the levels of inflammatory (258.98 pg/mL vs. 37.43 pg/mL, P < 0.0001), Th1-type (31.24 pg/mL vs. 24.46 pg/mL, P = 0.007), and Th17-type (36.79 pg/mL vs. 26.22 pg/mL, P < 0.0001) cytokines in critical COVID-19 patients. However, after Remdesivir treatment, the concentrations of Th2-type cytokines were significantly higher than before treatment (52.69 pg/mL vs. 37.09 pg/mL, P < 0.0001). In conclusion, Remdesivir led to decrease levels of Th1-type and Th17-type cytokines and increase Th2-type cytokines in critical COVID-19 patients 5 days after treatment.
Identifiants
pubmed: 37058846
pii: S0171-2985(23)00046-3
doi: 10.1016/j.imbio.2023.152378
pmc: PMC10036294
pii:
doi:
Substances chimiques
Cytokines
0
remdesivir
3QKI37EEHE
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
152378Informations de copyright
Copyright © 2023 Elsevier GmbH. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Infect Dis. 2020 Oct 1;222(9):1444-1451
pubmed: 32601708
Pharmacology. 2021;106(9-10):462-468
pubmed: 34515227
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
Sci Rep. 2022 May 4;12(1):7237
pubmed: 35508575
J Med Virol. 2022 May;94(5):2284-2289
pubmed: 35043405
Virus Res. 2020 Oct 15;288:198137
pubmed: 32827627
Front Immunol. 2021 Nov 09;12:771609
pubmed: 34858428
Pathogens. 2022 Feb 01;11(2):
pubmed: 35215138
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Eur Cytokine Netw. 2022 Jun 1;33(2):25-36
pubmed: 36266985
Front Pharmacol. 2022 Feb 14;13:802228
pubmed: 35237162
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Vaccines (Basel). 2021 Apr 29;9(5):
pubmed: 33946736
Zhonghua Shao Shang Za Zhi. 2020 Jun 20;36(6):471-475
pubmed: 32114747
SAGE Open Med Case Rep. 2022 Jan 11;10:2050313X211069023
pubmed: 35035974
BMC Infect Dis. 2021 Jan 18;21(1):79
pubmed: 33461503
BMC Infect Dis. 2022 Jan 28;22(1):96
pubmed: 35090394
Emerg Microbes Infect. 2020 Dec;9(1):1123-1130
pubmed: 32475230
Cytokine. 2021 Jul;143:155523
pubmed: 33840589
PLoS One. 2021 Apr 29;16(4):e0250330
pubmed: 33914789
BMJ Open. 2022 Mar 2;12(3):e048502
pubmed: 35236729
Br J Pharmacol. 2020 Nov;177(21):4813-4824
pubmed: 32329520
J Antimicrob Chemother. 2022 Apr 27;77(5):1404-1412
pubmed: 35233617
J Infect. 2022 Dec;85(6):702-769
pubmed: 36057383
Br J Pharmacol. 2021 Jun;178(11):2339-2350
pubmed: 33825201
Front Immunol. 2021 Jun 28;12:680188
pubmed: 34262564
Semin Immunopathol. 2017 Jul;39(5):529-539
pubmed: 28466096
Cytokine Growth Factor Rev. 2020 Jun;53:38-42
pubmed: 32360420
J Med Virol. 2022 Jan;94(1):384-387
pubmed: 34406670
Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32
pubmed: 22390970
Front Immunol. 2022 Jul 25;13:964179
pubmed: 35958594
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Signal Transduct Target Ther. 2021 Jul 7;6(1):255
pubmed: 34234112
Int Immunopharmacol. 2021 Apr;93:107407
pubmed: 33631512
Pulmonology. 2021 Sep-Oct;27(5):423-437
pubmed: 33867315
Inflamm Regen. 2020 Oct 1;40:37
pubmed: 33014208
BMJ Open. 2020 Nov 30;10(11):e041471
pubmed: 33257492
Front Immunol. 2021 Apr 30;12:646333
pubmed: 33995364
Front Immunol. 2021 Oct 04;12:741502
pubmed: 34671355
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
J Heart Lung Transplant. 2020 May;39(5):405-407
pubmed: 32362390
Mol Cell Biochem. 2021 Feb;476(2):675-687
pubmed: 33064288